| Document |
Document Title |
|
WO/2023/162836A1 |
The present invention provides: an active-ray-sensitive or radiation-sensitive resin composition comprising a resin (P) which can be decomposed by the action of an acid to increase the polarity thereof and a compound (Q) represented by a...
|
|
WO/2023/164057A1 |
The disclosure herein provides compounds and pharmaceutical compositions of Formula (I) for the modulation of IL-17A. Compounds and pharmaceutical compositions of Formula (I) are useful for the treatment of inflammatory conditions, such ...
|
|
WO/2023/158602A1 |
Disclosed are compounds of Formula I including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein G, Z, L, J, A and T are as defined in the disclosure. Also disclosed are compositions containing the compound...
|
|
WO/2023/156402A1 |
The present invention relates to the compounds of formula (I), and the N-oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof wherein the variables are defined according to the description. The com...
|
|
WO/2023/156886A1 |
Provided is a new organic metal complex that improves the light emission efficiency of a light-emitting device. The present invention provides an organic metal complex represented by general formula (G1). In the formula, X represents car...
|
|
WO/2023/158866A2 |
The disclosure includes a method of inhibiting a eukaryotic translation initiation factor 3e (eIF3e) comprising contacting the eIF3e with a compound or salt of the Formula I, where the variables, e.g., Y, Z, R, and R1R11 are defined here...
|
|
WO/2023/158795A1 |
Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
|
|
WO/2023/150874A1 |
Crystalline Forms of a compound of Formula I are provided: (I) Crystalline Form C is among the crystalline Forms identified. Form C has an X-ray powder diffraction (XRPD) pattern having characteristic peaks expressed in degrees 2Ɵ (±0....
|
|
WO/2023/019244A9 |
Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intoler...
|
|
WO/2023/154519A1 |
Provided are compounds of the Formula (I); or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.
|
|
WO/2023/150663A1 |
Provided herein are inhibitors of IGF-1R, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said IGF-1R inhibitory compounds for the treatment of disease.
|
|
WO/2023/145804A1 |
The purpose of the present invention is to provide a novel B0AT1 inhibitor. The present invention relates to a compound represented by formula (I): (the symbols in the formula are as described in the description) or a salt thereof. The p...
|
|
WO/2023/143355A1 |
The present invention provide compounds of formula (I-a), the preparation method thereof, pharmaceutcal compositions comprising the compounds, and the pharmaceutical uses for the treatment of cancer, autoimmune diseases, inflammatory dis...
|
|
WO/2023/146897A1 |
Described herein are selective HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular dis...
|
|
WO/2023/141852A1 |
Disclosed are compounds represented by formula 1a or formula 1b, and respective optical isomers, prodrugs, or pharmaceutically acceptable salts, and pharmaceutical compositions thereof, and the use thereof in the preparation of CDK2 inhi...
|
|
WO/2023/142985A1 |
The present invention belongs to the technical field of drug synthesis. Disclosed is a preparation method for a TGF-β-inhibiting anti-tumor drug. Compared with preparation methods in the existing technology, the number of reaction steps...
|
|
WO/2023/130540A1 |
Provided are a pyrazol benzamide compound represented by formula (I), a preparation method therefor and an application thereof, wherein R 1 and R 2 are independently selected from hydrogen, alkyl, amino, nitro, halogen, alkoxy, trifluoro...
|
|
WO/2023/131969A1 |
The present invention relates to an improved process for the preparation of Luliconazole. The present invention also provides a novel intermediate 1-cyanomethylimidazole methanesulphonate of Formula (V), process for its preparation and i...
|
|
WO/2023/130043A1 |
Provided herein are methods of using reversible monoacylglycerol lipase (MAGL) inhibitors for the treatment of anxiety and related conditions, including Generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-com...
|
|
WO/2023/125373A1 |
A method for preparing ruxolitinib intermediates, i.e. (R)-3-(4-halo-1H-pyrazol-1-yl)-3-cyclopentylpropionate (VI) and (R)-3-(4-halo-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (IX). In the method, 3-(4-halo-1H-pyrazol-1-yl)-3-cyclopent...
|
|
WO/2023/130050A1 |
Provided herein are methods of using reversible monoacylglycerol lipase (MAGL) inhibitors for the treatment and/or management of pain and related conditions, including post-operative pain, pain incident to an incision or wound, chronic p...
|
|
WO/2023/127883A1 |
The present invention provides a compound indicated by general formula (1) and having mPGES-1 inhibitory activity, a pharmaceutically acceptable salt thereof, or a solvate thereof (in the formula, R1 and R2 each independently indicate hy...
|
|
WO/2023/116812A1 |
The present disclosure provides a sulfonylurea compound. Specifically, provided are a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a use thereof in prep...
|
|
WO/2023/122289A1 |
A crystalline free acid form of (S)-4-(l-(3-(difluoromethyl)-l-methyl-5- (3-(trifluoromethyl)phenoxy)-lH-pyrazole-4-carboxamido)ethyl
) benzoic acid is provided. Methods of making and using the crystalline free acid form of (S)-4-( l-(3-...
|
|
WO/2023/118970A1 |
Disclosed is a system (100) and process (200) for recovery of Acrylonitrile (ACRN) from an ATBS monomer slurry. The system (100) comprises a first evaporator apparatus (104) and a second evaporator apparatus (109) connected in series and...
|
|
WO/2023/116884A1 |
The present disclosure provides a compound represented by structural formula (I) : or a pharmaceutically acceptable salt, or a stereoisomer thereof and their use in, e.g. treating a disease or disorder associated with CDK2. This disclosu...
|
|
WO/2023/118434A1 |
The present invention relates to novel pesticidally active amide compounds and in particular heteroaromatic amide compounds, to compositions comprising those compounds, and to their use in agriculture, for example in controlling insect p...
|
|
WO/2023/120452A1 |
This SREBP-1 inhibitor has inhibitory activity against SREBP-1 and does not have inhibitory activity against SREBP-2, the SREBP-1 inhibitor containing, as an active ingredient, one or more compounds from among compounds represented by fo...
|
|
WO/2023/115203A1 |
Disclosed are compounds of formula (I), wherein ring A is an 8-10 membered aromatic or partially aromatic bicyclic ring having 1-4 heteroatoms compositions thereof, wherein L1, L2, R1 to R4 and m are as defined in claim 1; and methods of...
|
|
WO/2023/115165A1 |
The present disclosure relates generally to compounds, their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.
|
|
WO/2023/122782A2 |
The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the...
|
|
WO/2023/111472A1 |
The present invention relates to a method for preparing 3,5-dinitropyrazole, comprising a step involving obtaining N-acetyl-3-nitropyrazole from pyrazole, and a step involving the sigmatropic rearrangement of the compound obtained.
|
|
WO/2023/110932A1 |
The present invention relates to the compounds of formula (I), and the N-oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof wherein the variables are defined according to the description, The com...
|
|
WO/2023/114977A1 |
Described herein are compounds useful as S1PR4 receptor antagonists, pharmaceutical compositions comprising said compounds, methods of making said compounds and pharmaceutical compositions, and methods of using said compounds and pharmac...
|
|
WO/2023/110871A1 |
A compound of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, which can be used as fungicides.
|
|
WO/2023/114188A1 |
Provided herein are compounds, such as compounds of Formula (I), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, and isotopically labeled derivatives thereof, and compositions...
|
|
WO/2023/112722A1 |
The present invention addresses the problem of providing: a compound suitably used for forming an optical anisotropic membrane that has excellent reverse wavelength dispersion property and moist heat durability; a polymerizable compositi...
|
|
WO/2023/114819A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/108036A1 |
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to sulfur- and selenium-containing compounds that act as agonists and/or antagonists of cannabi...
|
|
WO/2023/107714A2 |
This disclosure provides compounds and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating a condition, di...
|
|
WO/2023/105481A1 |
The present invention relates pharmaceutical compositions comprising a solid dispersion. More specifically, the present invention relates to pharmaceutical compositions for the treatment of Hepatitis B Virus (HBV). The present invention ...
|
|
WO/2023/101595A1 |
The present invention is directed towards compounds of formula (I), capable of binding to sortilin and thereby useful as sortilin inhibitors in the treatment of diseases, disorders and conditions associated with sortilin activity and bin...
|
|
WO/2023/101895A1 |
The present invention relates to Compounds of Formula (I) and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula (I), and methods of using ...
|
|
WO/2023/094830A1 |
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof wherein Ring A, Ring B, R1, R2, R3 and L are as defined herein. The compounds are antagonists of the resistant (R-type) voltage-gated calcium ion ch...
|
|
WO/2023/092175A1 |
The invention relates generally to a compound of Formula (I), wherein R1 is a bicyclic fused heterocyclic moiety and R2 is H or F. The compound of Formula (I) or a pharmaceutically acceptable salt thereof has potential medical use in the...
|
|
WO/2023/097195A1 |
This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
|
|
WO/2023/089632A1 |
The present disclosure provides new derivatives of pyrazole amide represented by the formula (Formula I) in which when R= -CH2-, then R1 may be one among benzene, 4-methyl benzene, 4-methoxy benzene, 4-chloro benzene, 4-fluoro benzene, 2...
|
|
WO/2023/088388A1 |
The present invention relates to a tetrahydrocarbazole compound, and a pharmaceutical composition and the use thereof. The tetrahydrocarbazole compound is a compound as represented by formula (I), an optical isomer or a pharmaceutically ...
|
|
WO/2023/091229A1 |
The present disclosure provides compounds having the general formula P-L-U, or pharmaceutically acceptable salts thereof, wherein P is a FOXO1 fusion protein binding moiety, L is a bivalent linker, and U is an ubiquitin ligase binding mo...
|
|
WO/2023/087503A1 |
Compound (3,5,5-trimethylcyclohex-2-enylidene)malononitrile reacts with different building blocks containing aldehyde groups to obtain four isophorone derivatives. The derivatives can mark mitochondria, lysosomes, endoplasmic reticula or...
|
